Brendan Saloner
Dados Biográficos
| ID | 5534824 |
|---|---|
| NOME | Brendan Saloner |
| PRENOMES | Brendan |
| SOBRENOME | Saloner |
| ASSINATURA | SALONER B |
| AFILIAÇÕES | Johns Hopkins University |
| ORCID | 0000-0001-9013-3023 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 42 |
| TOTAL DE CITAÇÕES | 19 |
| TOTAL COMO AUTOR | 42 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2013 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 2 |
Comparing Buprenorphine Treatment Outcomes Among Kentucky Medicaid Patients by Prescriber Specialty and Type
Background Buprenorphine is vital to improving health outcomes for patients with opioid use disorder (OUD). Little is known about variation in buprenorphine retention and related outcomes across different outpatient prescribers and settings.Methods Our 2020–2021 sample includes 10,709 Kentucky Medicaid-enrolled patients with OUD who received most of their buprenorphine prescriptions from primary care physicians, specialty care physicians, or adva…
A Qualitative Study on the Impact of Covid-19 on Overdose Risk from the Perspective of Survivors and Witnesses of Drug Overdose
INTRODUCTION: The COVID-19 pandemic had a devastating impact on people who use drugs (PWUD). Reductions in access to harm reduction tools and treatment services elevated rates of fatal overdose for many. We explore the mechanism through which these factors influenced the rise in overdose mortality during COVID-19 from the perspective of people with overdose encounters. METHODS: We conducted in-depth, semi-structured, 60-minute telephone-based int…
Mobile but still tied down
“I Really Didn’t Need Treatment, It Was Just a Way for Me Not to Go to Jail”
Mandated Drug Treatment in the Criminal Legal System—a Blunt but Necessary Tool
How should the state respond to people who commit low-level criminal offenses that stem from an untreated substance-use disorder? The issue has taken on a heightened importance amidst an ongoing national addiction crisis that has destabilized many U.S. communities and led to a myriad of harms. I offer a qualified defense for the use of legal mandates that require participation in drug treatment in lieu of jail time as one possible tool for reduci…
Implementation of carceral medicaid suspension and enrollment programs
Beliefs and Attitudes about Vermont’s Buprenorphine Decriminalization Law among Clinicians Who Prescribe Buprenorphine
BACKGROUND: On June 1, 2021, Vermont repealed all criminal penalties for possessing 224 milligrams or less of buprenorphine. We examined the potential impact of decriminalization with a survey of Vermont clinicians who prescribed buprenorphine within the past year. METHODS: All 638 Vermont clinicians with a waiver to prescribe buprenorphine were emailed the survey by Vermont Department of Health; 117 responded. We estimated the prevalence of the …
Disparities in Medication Use for Criminal Justice System–Referred Opioid Use Disorder Treatment
The results of this cross-sectional study suggest that targeted efforts to address persistent disparities in MOUD use among those with OUD and criminal justice system involvement are needed to address the poor health outcomes experienced by this population
Prescription Drug Dispensing and Patient Costs After Implementation of a No Behavioral Health Cost-Sharing Law
These findings suggest that the implementation of the New Mexico NCS law was successful in lowering out-of-pocket spending on prescription medications for MH/SUDs, but that there was no association of NCS with the volume of medications dispensed in the first 6 months after implementation. A key challenge is to identify policies that protect from high out-of-pocket spending while also promoting access to needed care
Association between high-threshold practices and buprenorphine treatment termination
Volatile drug use and overdose during the first year of the Covid-19 pandemic in the United States
A content analysis of legal policy responses to xylazine in the illicit drug supply in the United States
Returning home during the pandemic
Release, Reentry, and Reintegration During Covid-19
Introduction: The COVID-19 pandemic had a large negative impact on people in U.S. prisons. Expedited releases from prison were one strategy used to decrease morbidity and mortality from COVID-19. However, little is known about the reentry experiences of those being rapidly released from custody early in the pandemic. Methods: We aimed to examine the perspectives of former residents in the Federal Bureau of Prisons (BOP) regarding release, reentry…
Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
In this cohort study, the O-HQIP was associated with an increased initiation of buprenorphine in patients with OUD presenting to the ED. These findings suggest that statewide incentive programs may effectively improve outcomes for patients with OUD
Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
In this cross-sectional study of US pharmacy claims, state-mandated educational requirements beyond the initial training required to prescribe buprenorphine were associated with increased buprenorphine use over time. The findings suggest requiring education for buprenorphine prescribers and training in substance use disorder treatment for all controlled substance prescribers as an actionable proposal for increasing buprenorphine use, ultimately s…
Estimated Use of Prescription Medications Among Individuals Incarcerated in Jails and State Prisons in the US
In this cross-sectional, descriptive study of the distribution of prescription medications for chronic conditions in jails and state prisons, the findings suggest that there may be underuse of pharmacological treatment in correctional facilities relative to the nonincarcerated population. These findings, which require further investigation, may reflect inadequate care in jails and prisons and represent a critical public health issue
Exploring trauma and wellbeing of people who use drugs after witnessing overdose
Increased solitary drug use during Covid-19
Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic
BACKGROUND: The coronavirus disease-2019 pandemic has been associated with large increases in opioid-related mortality, yet it is unclear whether specific subpopulations were especially likely to discontinue buprenorphine treatment for opioid use disorder as the pandemic ensued. OBJECTIVE: The aim was to assess predictors of buprenorphine discontinuation in the early months of the coronavirus disease-2019 pandemic (April-July 2020) compared with …
A national survey of state laws regarding medications for opioid use disorder in problem-solving courts
Changes in Material Hardship During the First Year of the Covid-19 Pandemic
This article discusses the public's spending of the stimulus checks issued by the US government during 2020 and 2021
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the Covid-19 Pandemic
In a sample of continuously enrolled adult Medicaid beneficiaries, the COVID-19 public health emergency was not associated with decreased probability of buprenorphine possession, but was associated with decreased probability of urine drug testing and opioid treatment program services. These findings suggest patients in office-based settings retained access to buprenorphine despite decreased on-site services like urine drug tests, whereas patients…
Factors Associated with HIV Testing Among People Who Inject Drugs
Experiences with substance use disorder treatment during the Covid-19 pandemic
Accommodations to treatment made under the federal public health emergency appear to have sustained access to treatment in the early months of the pandemic. Since these changes are set to expire after the official public health emergency declaration, further action is needed to meet the ongoing need
The Effect of Public Insurance Expansions on Substance Use Disorder Treatment
We examine the effect of Medicaid expansion under the Affordable Care Act (ACA) on substance use disorder (SUD) treatment utilization and financing. We combine data on admissions to specialty facilities and Medicaid-reimbursed prescriptions for medications commonly used to treat SUDs in nonspecialty outpatient settings with an event-study design. Several findings emerge from our study. First, among patients receiving specialty care, Medicaid cove…
Ending the Opioid Epidemic Requires a Historic Investment in Medication‐assisted Treatment
Blacks And Hispanics Are Less Likely Than Whites To Complete Addiction Treatment, Largely Due To Socioeconomic Factors
More than one-third of the approximately two million people entering publicly funded substance abuse treatment in the United States do not complete treatment. Additionally, racial and ethnic minorities with addiction disorders, who constitute approximately 40 percent of the admissions in publicly funded substance abuse treatment programs, may be particularly at risk for poor outcomes. Using national data, we found that blacks and Hispanics were 3…
Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010
IMPORTANCE: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. OBJECTIVE: To determine the association between the presence of state medical cannabis laws and opioid a…
Access Points for the Underserved
BACKGROUND: Federally Qualified Health Centers (FQHCs) are a vital source of primary care for underserved populations, such as Medicaid enrollees and the uninsured. Their role in delivering care may increase through new funding allocations in the Affordable Care Act and expanded Medicaid programs across many states. OBJECTIVE: Examine differences in appointment availability and wait-times for new patient visits between FQHCs and other providers. …
Predicting High-cost Pediatric Patients
The proposed prediction tool, comprising a simple series of PRH measures, accurately stratifies pediatric populations by their risk of incurring high health care costs
Primary Care Appointment Availability for Medicaid Patients
BACKGROUND: Arkansas and Iowa received waivers from the federal government in 2014 to use federal Medicaid expansion funding to enroll beneficiaries in commercial insurance plans on the Marketplaces. One key hypothesis of these "private option" or "premium assistance" programs was that Medicaid beneficiaries would experience increased access to care. In this study, we compare new patient primary care appointment availability and wait-times for be…
Health Care Experiences of Latino Children in Emerging and Traditional Destinations
BACKGROUND: Latino populations have disproportionately moved to areas in the Southeast and Midwest (emerging destinations), outside traditional Latino enclaves, in recent years. OBJECTIVE: To examine whether health care experiences differ between traditional and emerging destinations for Latino children. RESEARCH DESIGN: We defined traditional and emerging destination counties based on levels and changes in the Latino population between 2000 and …
Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment
BACKGROUND: Opioid agonist therapy (OAT) is the standard of care for pregnant women with opioid use disorder (OUD). Medicaid coverage policies may strongly influence OAT use in this group. OBJECTIVE: To examine the association between Medicaid coverage of methadone maintenance and planned use of OAT in the publicly funded treatment system. RESEARCH DESIGN: Retrospective cross-sectional analysis of treatment admissions in 30 states extracted from …
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population
BACKGROUND: Buprenorphine-naloxone treatment for opioid use disorder has rapidly expanded, yet little is known about treatment outcomes among patients in the general population. OBJECTIVE: To examine predictors of treatment duration, dosage, and continuity in a diverse community setting. RESEARCH DESIGN: We examined QuintilesIMS Real World Data, an all-payer, pharmacy claims database, to conduct an analysis of individuals age 18 years and above i…
A Public Health Strategy for the Opioid Crisis
Drug overdose is now the leading cause of injury death in the United States. Most overdose fatalities involve opioids, which include prescription medication, heroin, and illicit fentanyl. Current data reveal that the overdose crisis affects all demographic groups and that overdose rates are now rising most rapidly among African Americans. We provide a public health perspective that can be used to mobilize a comprehensive local, state, and nationa…
Ending the Opioid Epidemic Requires a Historic Investment in Medication‐assisted Treatment
Response to Pacula and Powell
The Effect of Public Insurance Expansions on Substance Use Disorder Treatment
We examine the effect of Medicaid expansion under the Affordable Care Act (ACA) on substance use disorder (SUD) treatment utilization and financing. We combine data on admissions to specialty facilities and Medicaid-reimbursed prescriptions for medications commonly used to treat SUDs in nonspecialty outpatient settings with an event-study design. Several findings emerge from our study. First, among patients receiving specialty care, Medicaid cove…
Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder
BACKGROUND: Although buprenorphine is an evidence-based treatment for opioid use disorder (OUD), it is unknown whether buprenorphine use may affect patients' adherence to treatments for chronic, unrelated conditions. OBJECTIVES: To quantify the effect of buprenorphine treatment on patient adherence to 5 therapeutic classes: (1) antilipids; (2) antipsychotics; (3) antiepileptics; (4) antidiabetics; and (5) antidepressants. RESEARCH DESIGN: This wa…
An Epidemic in the Midst of a Pandemic
Ideas and Opinions2 April 2020An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19FREEG. Caleb Alexander, MD, MS, Kenneth B. Stoller, MD, Rebecca L. Haffajee, JD, PhD, MPH, and Brendan Saloner, PhDG. Caleb Alexander, MD, MSJohns Hopkins Bloomberg School of Public Health and Johns Hopkins Medicine, Baltimore, Maryland (G.C.A.), Kenneth B. Stoller, MDJohns Hopkins University School of Medicine, Baltimore, Maryland (K.B.S.), Rebe…
The Impact of Various Risk Assessment Time Frames on the Performance of Opioid Overdose Forecasting Models
BACKGROUND: An individual's risk for future opioid overdoses is usually assessed using a 12-month "lookback" period. Given the potential urgency of acting rapidly, we compared the performance of alternative predictive models with risk information from the past 3, 6, 9, and 12 months. METHODS: We included 1,014,033 Maryland residents aged 18-80 with at least 1 opioid prescription and no recorded death in 2015. We used 2015 Maryland prescription dr…
Performance of a Predictive Model versus Prescription-Based Thresholds in Identifying Patients at Risk of Fatal Opioid Overdose
Background: Prescription Drug Monitoring Programs (PDMPs) collect controlled substance prescriptions dispensed within a state. Many PDMP programs perform targeted outreach (i.e., “unsolicited reporting”) for patients who exceed numerical thresholds, however, the degree to which patients at highest risk of fatal opioid overdose are identified has not been compared with one another or with a predictive model. Methods: A retrospective analysis was p…
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
AIM: The aim of this study was to characterize quality of buprenorphine care for opioid use disorder (OUD) by quantifying buprenorphine initiation, engagement, and maintenance for individuals in a large, diverse, real-world cohort in the United States. DESIGN: This was a retrospective cohort analysis. SETTING: OUD treatment in the outpatient setting. PARTICIPANTS: A total of 45,210 commercially insured and Medicare Advantage (MA) enrollees 18 yea…
A national survey of state laws regarding medications for opioid use disorder in problem-solving courts
Changes in Material Hardship During the First Year of the Covid-19 Pandemic
This article discusses the public's spending of the stimulus checks issued by the US government during 2020 and 2021
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the Covid-19 Pandemic
In a sample of continuously enrolled adult Medicaid beneficiaries, the COVID-19 public health emergency was not associated with decreased probability of buprenorphine possession, but was associated with decreased probability of urine drug testing and opioid treatment program services. These findings suggest patients in office-based settings retained access to buprenorphine despite decreased on-site services like urine drug tests, whereas patients…
Factors Associated with HIV Testing Among People Who Inject Drugs
Experiences with substance use disorder treatment during the Covid-19 pandemic
Accommodations to treatment made under the federal public health emergency appear to have sustained access to treatment in the early months of the pandemic. Since these changes are set to expire after the official public health emergency declaration, further action is needed to meet the ongoing need
Returning home during the pandemic
Release, Reentry, and Reintegration During Covid-19
Introduction: The COVID-19 pandemic had a large negative impact on people in U.S. prisons. Expedited releases from prison were one strategy used to decrease morbidity and mortality from COVID-19. However, little is known about the reentry experiences of those being rapidly released from custody early in the pandemic. Methods: We aimed to examine the perspectives of former residents in the Federal Bureau of Prisons (BOP) regarding release, reentry…
Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
In this cohort study, the O-HQIP was associated with an increased initiation of buprenorphine in patients with OUD presenting to the ED. These findings suggest that statewide incentive programs may effectively improve outcomes for patients with OUD
Medicine (33 obras) · Opioid Use Disorder Treatment (28 obras) · Psychiatry (20 obras) · HIV, Drug Use, Sexual Risk (18 obras) · Internal Medicine (18 obras) · Opioid (16 obras) · Buprenorphine (14 obras) · Substance Abuse Treatment and Outcomes (14 obras) · Family medicine (13 obras) · Health care (13 obras)